Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Apr;35(4):679-684.
doi: 10.1007/s10552-023-01825-5. Epub 2023 Nov 28.

Evaluating implementation of NCCN guideline-directed genetic screening recommendations for patients with pancreatic ductal adenocarcinoma

Aditya K Ghosh  1 , Sheena Bhushan  2 , Oluseyi Abidoye  3 , Shane S Robinson  2 , Ania Izabela Rynarzewska  4 , Devi Sampat  5
Affiliations
Observational Study

Evaluating implementation of NCCN guideline-directed genetic screening recommendations for patients with pancreatic ductal adenocarcinoma

Aditya K Ghosh et al. Cancer Causes Control. 2024 Apr.

Abstract

Purpose: In 2019, the National Comprehensive Cancer Network (NCCN) recommended genetic testing for all patients with pancreatic ductal adenocarcinoma (PDAC). To evaluate the status of implementation of these guidelines in a loco-regional setting, we performed a retrospective, observational study among patients with newly diagnosed PDAC who received oncologic care at Northeast Georgia Medical Center in Georgia.

Methods: Chart abstraction of patients with newly diagnosed PDAC from 1 January 2020 to 31 December 2021 was performed to include information on genetic testing recommendation and completion, and time from diagnosis to testing. The deidentified dataset was then analyzed using appropriate descriptive and associative statistical testing.

Results: Of the cohort of 109 patients, 32 (29.4%) completed genetic screening; 16 (14.7%) were screened within 10 days of diagnosis. Among the 77 (70.6%) patients who did not receive genetic screening, 45 (41.3%) were not recommended genetic screening despite treatment intent with standard of care therapy. However, 32 (29.4%) were not recommended genetic screening in conjunction with a desire to pursue palliative care/hospice/or due to terminal illness.

Conclusions: The study highlighted the gap in implementation of NCCN guideline-directed genetic testing in PDAC patients as only a third underwent testing suggesting the need for systematic processes to facilitate testing. The test was more likely to be completed if done early in the course, especially soon after the diagnosis. Research is needed to explore discussing genetic testing for the large proportion of patients who are terminally ill at diagnosis where genetic screening would potentially benefit the family members.

Keywords: Genetic testing; NCCN; Pancreatic ductal adenocarcinoma.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/caac.21763 - DOI - PubMed
    1. Petersen GM (2016) Familial pancreatic cancer. Semin Oncol 43(5):548–553. https://doi.org/10.1053/j.seminoncol.2016.09.002 - DOI - PubMed - PMC
    1. Pilarski R (2019) The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book 39:79–86. https://doi.org/10.1200/EDBK_238977 - DOI - PubMed
    1. Brown TJ, Reiss KA (2021) PARP inhibitors in pancreatic cancer. Cancer J 27(6):465–475 - DOI - PubMed - PMC
    1. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM, Hruban RH (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16(2):342–346. https://doi.org/10.1158/1055-9965.EPI-06-0783 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources